GlobeNewswire·Nov 10, 2026, 9:40 PM ET

Prime Medicine Announces Pricing of Public Offering of Common Stock

Prime Medicine, Inc. (Nasdaq: PRME) priced an underwritten public offering of 35,714,286 shares of common stock at $3.50 per share.
The company granted underwriters a 30-day option to purchase up to 5,357,142 additional shares.
Gross proceeds are expected to be approximately $125.0 million before deducting underwriting discounts, commissions, & offering expenses, excluding any exercise of the option.
All shares in the offering are being sold by Prime Medicine.
The offering is expected to close on or about November 12, 2026, subject to customary closing conditions.
Jefferies, TD Cowen, & Goldman Sachs & Co. LLC are acting as joint book-running managers.
Oppenheimer & Co. & LifeSci Capital are acting as passive book-running managers.
The offering is made pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the SEC.
Prime Medicine is a biotechnology company developing gene editing therapies using its proprietary Prime Editing platform.
The company has a portfolio of investigational programs focused on liver, lung, & immunology and oncology.
Investor contacts are Gregory Dearborn (Prime Medicine) & Hannah Deresiewicz (Precision AQ).